Recent changes.
Catalyst dates move. This page lists every date on the biotech catalyst calendar that has changed in the last 30 days, and every row withdrawn in that period, with the date it moved from. A row that moves keeps its identity, so a calendar subscription updates the event in place rather than adding a second one. Nothing is ever deleted quietly.
Last compiled .
| Was | Now | Lane | Company | Event | Source |
|---|---|---|---|---|---|
| 22 Sept 2026 | Clinical | Merck Sharp & Dohme LLC | As of 20 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 October 2026. | NCT05468697 | |
| 30 Aug 2026 | Clinical | ReCode Therapeutics | As of 19 August 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, in November 2026. | NCT06237335 | |
| 14 Oct 2026 | Clinical | GlaxoSmithKline | As of 17 August 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 16 September 2026. | NCT07596173 | |
| 30 Nov 2026 | Clinical | Mirati Therapeutics Inc. | As of 14 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 October 2026. | NCT05853575 |